Literature DB >> 20036698

Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40)) are modulated by sulfate moieties of heparin.

Nienke M Timmer1, Tom J J Schirris, Ilona B Bruinsma, Irene Otte-Höller, Toin H van Kuppevelt, Robert M W de Waal, Marcel M Verbeek.   

Abstract

Glycosaminoglycans (GAGs), in particular as part of heparan sulfate proteoglycans, are associated with cerebral amyloid angiopathy (CAA). Similarly, GAGs are also associated with the severe CAA found in patients suffering from hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D), where the amyloid beta (Abeta) peptide contains the Dutch mutation (DAbeta(1-40)). This suggests a role for GAGs in vascular Abeta aggregation. It was the aim of this study to investigate the effect of different GAGs (heparin, chondroitin sulfate, heparan sulfate), the macromolecule dextran sulfate and, using desulfated heparins, the role of GAG sulfate moieties on the in vitro aggregation of CAA-associated DAbeta(1-40) and on DAbeta(1-40)-induced toxicity of cultured cerebrovascular cells. We also aimed to study the in vivo distribution of various sulfated heparan sulfate GAG epitopes in CAA. Of all GAGs tested, heparin was the strongest inducer of aggregation of DAbeta(1-40) in the different aggregation assays, with both heparin and heparan sulfate reducing Abeta-induced cellular toxicity. Furthermore, (partial) removal of the sulfate moieties of heparin partially abolished the effects of heparin on aggregation and cellular toxicity, suggesting an essential role for the sulfate moieties in heparin. Finally, we demonstrated the in vivo association of sulfated heparan sulfate (HS) GAGs with CAA. We conclude that sulfate moieties within GAGs, like heparin and HS, have an important role in Abeta aggregation in CAA and in Abeta-mediated toxicity of cerebrovascular cells. Copyright 2010 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036698     DOI: 10.1016/j.neures.2009.12.012

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  14 in total

Review 1.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

2.  Glycosaminoglycans have variable effects on α-synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils.

Authors:  Surabhi Mehra; Dhiman Ghosh; Rakesh Kumar; Mrityunjoy Mondal; Laxmikant G Gadhe; Subhadeep Das; Arunagiri Anoop; Narendra N Jha; Reeba S Jacob; Debdeep Chatterjee; Soumik Ray; Nitu Singh; Ashutosh Kumar; Samir K Maji
Journal:  J Biol Chem       Date:  2018-06-29       Impact factor: 5.157

3.  Heparin binds 8 kDa gelsolin cross-β-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension.

Authors:  James P Solomon; Steve Bourgault; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-03-15       Impact factor: 3.162

4.  Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction.

Authors:  Douglas J Martin; Marina Ramirez-Alvarado
Journal:  Biophys Chem       Date:  2011-05-18       Impact factor: 2.352

5.  A peptide found by phage display discriminates a specific structure of a trisaccharide in heparin.

Authors:  Tomio Yabe; Ritsuko Hosoda-Yabe; Yoshihiro Kanamaru; Makoto Kiso
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

Review 6.  Glycosaminoglycans in Neurodegenerative Diseases.

Authors:  Weihua Jin; Fuming Zhang; Robert J Linhardt
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 7.  Heparan sulfate S-domains and extracellular sulfatases (Sulfs): their possible roles in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji
Journal:  Glycoconj J       Date:  2018-07-12       Impact factor: 2.916

8.  Heparanase overexpression impedes perivascular clearance of amyloid-β from murine brain: relevance to Alzheimer's disease.

Authors:  Xiao Zhang; Paul O'Callaghan; Honglian Li; Yingxia Tan; Ganlin Zhang; Uri Barash; Xiaomin Wang; Lars Lannfelt; Israel Vlodavsky; Ulf Lindahl; Jin-Ping Li
Journal:  Acta Neuropathol Commun       Date:  2021-05-10       Impact factor: 7.801

9.  Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy.

Authors:  Byung Hee Han; Meng-liang Zhou; Ananth K Vellimana; Eric Milner; David H Kim; Jacob K Greenberg; Wenhua Chu; Robert H Mach; Gregory J Zipfel
Journal:  Mol Neurodegener       Date:  2011-12-22       Impact factor: 14.195

10.  Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.

Authors:  Elisanne A L M Biemans; Lieke Jäkel; Robert M W de Waal; H Bea Kuiperij; Marcel M Verbeek
Journal:  J Neurosci Res       Date:  2016-10-11       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.